https://www.28bio.com https://www.28bio.com/resources/application-notes https://www.28bio.com/applications/preclinical-safety https://www.28bio.com/legal/fcoi-policy https://www.28bio.com/legal/privacy-policy https://www.28bio.com/legal/terms-of-use https://www.28bio.com/applications/preclinical-efficacy https://www.28bio.com/resources/scientific-posters https://www.28bio.com/resources/publications https://www.28bio.com/company/team https://www.28bio.com/company/mission https://www.28bio.com/technology https://www.28bio.com/products-services/cns-3d-technology https://www.28bio.com/products-services/pns-3d-technology https://www.28bio.com/contact https://www.28bio.com/products-services/cns-3d-organoids https://www.28bio.com/products-services/cns-3d-services https://www.28bio.com/products-services/pns-3d-services https://www.28bio.com/organoid-intelligence https://www.28bio.com/resources/resource-library https://www.28bio.com/resources/protocols https://www.28bio.com/resources/webinars https://www.28bio.com/company/newsroom https://www.28bio.com/company/events https://www.28bio.com/resources/faqs https://www.28bio.com/company/careers https://www.28bio.com/28bionews/overview https://www.28bio.com/28bionews/28bionews---in-the-news-01 https://www.28bio.com/28bionews/28bionews---spotlights https://www.28bio.com/28bionews/28bionews---case-studies https://www.28bio.com/myelinated-organoids-contact https://www.28bio.com/careers/field-application-scientist https://www.28bio.com/news-categories/news https://www.28bio.com/news-categories/press https://www.28bio.com/events/28biolive https://www.28bio.com/events/2nd-adc-toxicity-summit-2024 https://www.28bio.com/events/adc-toxicity-summit-2025 https://www.28bio.com/events/bio-international-2026 https://www.28bio.com/events/bio-international-convention-2025 https://www.28bio.com/events/functional-neural-activity-as-a-predictor-of-cns-toxicity-across-modalities https://www.28bio.com/events/gen-spotlight-virtual-event-organoids https://www.28bio.com/events/labroots-neuroscience-virtual-event-series-2026 https://www.28bio.com/events/mps-world-summit-2023 https://www.28bio.com/events/mps-world-summit-2024 https://www.28bio.com/events/mps-world-summit-2025 https://www.28bio.com/events/mps-world-summit-2026 https://www.28bio.com/events/pns-2024-annual-meeting https://www.28bio.com/events/sfn-2024-conference https://www.28bio.com/events/slas-2023-conference https://www.28bio.com/events/society-of-toxicology-2023-highlights https://www.28bio.com/events/society-of-toxicology-2024-conference https://www.28bio.com/events/society-of-toxicology-2025-conference https://www.28bio.com/events/sot-2026 https://www.28bio.com/events/sps-2025 https://www.28bio.com/events/word-plus-2025-conference https://www.28bio.com/events/world-adc-2025 https://www.28bio.com/resource/2d-vs-co-culture-neurotoxicity-testing https://www.28bio.com/resource/3d-cns-model-glial-cell-research https://www.28bio.com/resource/3d-microelectrode-peripheral-nerve-model https://www.28bio.com/resource/3d-model-peripheral-neuropathy https://www.28bio.com/resource/3d-neuronal-mps-model https://www.28bio.com/resource/3d-organoid-neurotoxicity-screening https://www.28bio.com/resource/adc-neurotoxicity-predictive-assays-webinar https://www.28bio.com/resource/als-teleneurology-biobank-initiative https://www.28bio.com/resource/altered-network-genetic-epilepsy https://www.28bio.com/resource/antiseizure-drug-testing-app-note https://www.28bio.com/resource/brain-organoid-curi-bio-app-note https://www.28bio.com/resource/calcium-signal-screening-ipsc-neural-spheroids https://www.28bio.com/resource/chemotherapy-induced-peripheral-neuropathy-assessment-in-pns-3d-technology https://www.28bio.com/resource/cipn-case-study-nerve-toxicity-screening https://www.28bio.com/resource/clinical-seizure-liability https://www.28bio.com/resource/cns-3d-brain-organoids-neuromodulation-advantages https://www.28bio.com/resource/cns-3d-organoids-384-well-plate-protocol https://www.28bio.com/resource/cns-3d-organoids-96-well-plate-protocol https://www.28bio.com/resource/cns-3d-organoids-flipr-assay https://www.28bio.com/resource/cns-3d-organoids-predict-neurotoxicity-small-molecules-aso https://www.28bio.com/resource/cns-3d-organoids-product-sheet https://www.28bio.com/resource/cognitive-biomarker-dementia https://www.28bio.com/resource/disease-modeling-in-cns-3d-technology https://www.28bio.com/resource/dual-human-cell-system-peripheral-neuropathy-testing https://www.28bio.com/resource/electrophysiology-neurotoxicity-screening https://www.28bio.com/resource/functional-organoids-disease-modeling https://www.28bio.com/resource/future-of-organoid-intelligence https://www.28bio.com/resource/high-throughput-3d-pns-model https://www.28bio.com/resource/high-throughput-neurotoxicity-prediction https://www.28bio.com/resource/high-throughput-neurotoxicity-screening https://www.28bio.com/resource/hipsc-neurospheroid-seizurogenicity https://www.28bio.com/resource/human-co-culture-model-neurotoxicity-testing https://www.28bio.com/resource/human-drg-ectopic-activity-neuropathic-pain https://www.28bio.com/resource/human-ipsc-brain-model https://www.28bio.com/resource/human-nerve-conduction-velocity-testing https://www.28bio.com/resource/human-peripheral-nerve-preclinical-neurotoxicity-assay https://www.28bio.com/resource/human-schwann-cells-peripheral-neuropathy-research https://www.28bio.com/resource/ipsc-cortical-organoids-rett-syndrome https://www.28bio.com/resource/ipsc-neurotoxicity-screening https://www.28bio.com/resource/ipsc-organoids-rett-cdd-drug-screening https://www.28bio.com/resource/ipsc-pain-model-opioid-research https://www.28bio.com/resource/microengineered-peripheral-nerve-chip https://www.28bio.com/resource/modeling-cdkl5-deficiency-disorder-with-cns-3d-organoids-for-streamlined-target-discovery https://www.28bio.com/resource/motor-neuron-disease-model https://www.28bio.com/resource/myelin-disruption-repair-therapeutic-assessment https://www.28bio.com/resource/nerve-on-a-chip-neurotoxicity-screening https://www.28bio.com/resource/neurological-drug-discovery-toxicology-webinar https://www.28bio.com/resource/neurological-stem-cell-therapies-webinar https://www.28bio.com/resource/neurotoxicity-screening-ipsc-3d-neural-cultures https://www.28bio.com/resource/organoid-intelligence https://www.28bio.com/resource/organoid-neurotoxicity-testing-app-note https://www.28bio.com/resource/paroxetine-developmental-neurotoxicity https://www.28bio.com/resource/peripheral-neuropathy-screening https://www.28bio.com/resource/pns-3d-organoid-services-product-sheet https://www.28bio.com/resource/pns-electrophysiology-functional-responses https://www.28bio.com/resource/pns-neurotoxicity-screening https://www.28bio.com/resource/pns-organoid-neurotoxicity-testing https://www.28bio.com/resource/pns-organoid-toxicity-screening https://www.28bio.com/resource/pns-organoids-cipn https://www.28bio.com/resource/preclinical-myelinated-screening https://www.28bio.com/resource/predicting-clinical-neurotoxicity-using-functional-organoids https://www.28bio.com/resource/predicting-seizure-liability-brain-organoids-on-demand https://www.28bio.com/resource/rat-drg-microglia-neurotoxicity-model https://www.28bio.com/resource/reproducible-brain-organoids https://www.28bio.com/resource/resources-aav-transduction-brain-organoids-app-note https://www.28bio.com/resource/rotenone-neurotoxicity-brain-model https://www.28bio.com/resource/sarm1-inhibition-neuroprotection https://www.28bio.com/resource/screening-neural-network-activity-organoids https://www.28bio.com/resource/takeda-brain-organoids https://www.28bio.com/resource/takeda-brain-organoids-publication https://www.28bio.com/resource-categories/app-notes https://www.28bio.com/resource-categories/cns https://www.28bio.com/resource-categories/cns-3d-organoids https://www.28bio.com/resource-categories/cns-3d-services https://www.28bio.com/resource-categories/efficacy https://www.28bio.com/resource-categories/pns https://www.28bio.com/resource-categories/pns-3d-services https://www.28bio.com/resource-categories/posters https://www.28bio.com/resource-categories/product-sheets https://www.28bio.com/resource-categories/protocols https://www.28bio.com/resource-categories/publications https://www.28bio.com/resource-categories/safety https://www.28bio.com/resource-categories/studies https://www.28bio.com/resource-categories/webinars https://www.28bio.com/company/post/28bio-announces-nexon-tm-neurotechnology-platform-powered-by-engineered-human-brains https://www.28bio.com/company/post/28bio-endurance-study-predicts-clinical-seizure-liability https://www.28bio.com/company/post/accelerating-organoid-adoption-set-to-transform-cancer-drugs https://www.28bio.com/company/post/axosim-acquires-brain-organoid-stemonix https://www.28bio.com/company/post/axosim-appoints-stuart-gibb-vp-sales-marketing https://www.28bio.com/company/post/axosim-board-co-chairs-dale-pfost-david-weiner https://www.28bio.com/company/post/axosim-ceo-alif-saleh https://www.28bio.com/company/post/axosim-enters-into-a-definitive-agreement-to-acquire-vyant-bios-stemonix-assets https://www.28bio.com/company/post/axosim-scoops-up-tech-from-vyant-subsidiary https://www.28bio.com/company/post/cns-3d-myelinated-organoids-announcement https://www.28bio.com/company/post/fdas-shift-from-animal-testing-opens-doors-for-organoid-makers https://www.28bio.com/company/post/grant-neurodegenerative-disease https://www.28bio.com/company/post/grant-neurodegenerative-disease-awardee-announcement https://www.28bio.com/company/post/myelin-organoids-demyelinating-disease https://www.28bio.com/company/post/neuro-drugs-are-still-faltering-despite-rising-investment https://www.28bio.com/company/post/organoid-intelligence-learning-neural-tissue https://www.28bio.com/company/post/organoid-neurotoxicity-testing https://www.28bio.com/company/post/takeda-cns3d-organoids-neurotoxicity-assessment https://www.28bio.com/company/post/the-clumps-of-brain-cells-that-can-play-pac-man